The closing price of Novavax, Inc. (NASDAQ: NVAX) was $6.02 for the day, up 9.45% from the previous closing price of $5.50. In other words, the price has increased by $+0.52 from its previous closing price. On the day, 16078666 shares were traded.
Ratios:
Our analysis of NVAX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.64 and its Current Ratio is at 0.69.
On April 20, 2023, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $55 to $10.
B. Riley Securities Downgraded its Buy to Neutral on March 01, 2023, whereas the target price for the stock was revised from $29 to $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 10 when Glenn Gregory M bought 1,000 shares for $6.50 per share. The transaction valued at 6,500 led to the insider holds 14,473 shares of the business.
Glenn Gregory M bought 2,000 shares of NVAX for $14,088 on Mar 07. The President, R&D now owns 13,473 shares after completing the transaction at $7.04 per share. On Mar 06, another insider, Glenn Gregory M, who serves as the President, R&D of the company, bought 3,000 shares for $7.48 each. As a result, the insider paid 22,454 and bolstered with 11,473 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 715.12M and an Enterprise Value of 286.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.68. Its current Enterprise Value per Revenue stands at 0.29 whereas that against EBITDA is -0.57.
Stock Price History:
Over the past 52 weeks, NVAX has reached a high of $11.36, while it has fallen to a 52-week low of $3.53. The 50-Day Moving Average of the stock is 4.53, while the 200-Day Moving Average is calculated to be 6.65.
Shares Statistics:
NVAX traded an average of 8.55M shares per day over the past three months and 11.78M shares per day over the past ten days. A total of 118.79M shares are outstanding, with a floating share count of 111.93M. Insiders hold about 5.77% of the company’s shares, while institutions hold 65.68% stake in the company. Shares short for NVAX as of Jan 31, 2024 were 52.09M with a Short Ratio of 6.09, compared to 49.2M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 43.85% and a Short% of Float of 52.66%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of $0.08 and a low estimate of -$1.29, while EPS last year was -$2.28. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.28 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$3.45 and -$5.25 for the fiscal current year, implying an average EPS of -$4.21. EPS for the following year is -$0.39, with 6 analysts recommending between $3.02 and -$3.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $377.5M to a low estimate of $270.73M. As of the current estimate, Novavax, Inc.’s year-ago sales were $357.4M, an estimated decrease of -9.90% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $292.33M, an increase of 261.10% over than the figure of -$9.90% in the same quarter last year. There is a high estimate of $302M for the next quarter, whereas the lowest estimate is $275M.
A total of 6 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.07B, while the lowest revenue estimate was $963.09M, resulting in an average revenue estimate of $1.01B. In the same quarter a year ago, actual revenue was $1.98B, down -48.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $969.56M in the next fiscal year. The high estimate is $1.5B and the low estimate is $640M. The average revenue growth estimate for next year is down -4.40% from the average revenue estimate for this year.
